Matinas BioPharma Holdings, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request identifies 2022 Q4, this is an annual filing; the supplied text does not provide clear stand-alone fourth-quarter financial results. Financial amounts below are in millions of dollars unless stated otherwise.
Business context
Matinas is a clinical-stage biopharmaceutical company developing therapies using its lipid nanocrystal (LNC) delivery platform. Its lead candidate, MAT2203, is an oral formulation of amphotericin B being developed initially for cryptococcal meningitis (CM). The company has no product sales. It is also pursuing LNC collaborations and nucleic-acid delivery programs.
Financial performance and position
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Contract revenue | $3.188 | $0.033 |
| Research and development expense | $16.678 | $14.583 |
| General and administrative expense | $11.100 | $10.185 |
| Total operating expenses | $27.778 | $24.768 |
| Loss from operations | $(24.590) | $(24.735) |
| Net loss | $(20.997) | $(23.283) |
| Net loss per share, basic and diluted | $(0.10) | $(0.11) |
| Net cash used in operating activities | $(19.156) | $(15.223) |
FY 2022 contract revenue came primarily from the BioNTech research collaboration, including recognition of part of its $2.75 million exclusivity fee and research services; it is not product revenue. Revenue increased substantially from the small Genentech feasibility-study revenue recorded in 2021. Operating expenses rose about 12%; R&D increased about 14% and G&A about 9%. Net loss narrowed about 10%, helped in part by $3.491 million of proceeds from selling New Jersey tax losses and credits, compared with $1.328 million in 2021. Gross margin is not meaningful for this pre-commercial business.
At year-end, cash and cash equivalents were $6.830 million, marketable debt securities were $21.933 million, and restricted cash was $0.250 million. Current assets were $34.532 million and current liabilities $4.286 million. Total liabilities were $8.182 million, including $4.095 million of operating lease liabilities and $0.029 million of finance lease liabilities; the filing reports no material conventional borrowing debt. Accumulated deficit was $152.631 million.
Operating cash use increased $3.933 million year over year. Investing activities provided $4.877 million, primarily reflecting net securities transactions; financing activities provided $0.079 million, versus $6.965 million in 2021, when ATM stock sales generated $5.580 million net. The 2022 unrealized loss on available-for-sale securities was $0.679 million.
Material changes, outlook and risks
- Management said available cash, cash equivalents and marketable securities were expected to fund planned operations into the second quarter of 2024. This estimate depends on assumptions and the company said it will need additional financing; failure to raise capital could force delays, reductions or termination of programs.
- Management expected 2023 R&D and G&A spending to be relatively consistent with 2022. It expected operating cash use in 2023 to be similar to 2022. No product-revenue or profitability guidance was provided.
- Interim EnACT Cohort 4 results reported at IDWeek 2022 included mean early fungicidal activity of 0.353 log10 CFU/mL/day (95% CI 0.22–0.49), 85% interim 18-week survival among 40 MAT2203-treated patients, and fewer Grade 3-or-higher clinical adverse events than standard of care (42% versus 59%). These are interim clinical findings, not proof of regulatory approval or commercial success. Final EnACT analysis was anticipated in Q2 2023.
- The planned CM pivotal Phase 3 trial was described as a roughly 270-patient, three-arm non-inferiority study, with two MAT2203 regimens and a standard-of-care control. The primary endpoint is two-week all-cause mortality; FDA approval and trial execution remain uncertain.
- The company planned an FDA discussion in Q2 2023 about a possible separate Phase 3 study in other invasive fungal infections. It was seeking non-dilutive funding or partners before proceeding and had slowed the Thermo Fisher manufacturing technology transfer pending financing.
- MAT2501 development was paused to focus resources on MAT2203 and the LNC platform. The company said it was working with the Cystic Fibrosis Foundation to wind up the agreement and did not anticipate receiving the remaining award commitment. LYPDISO development was discontinued after the company failed to identify a development partner.
- Collaborations included Genentech, whose feasibility agreement was extended through 2023, and BioNTech, whose research collaboration began in 2022. A possible BioNTech platform license had not been executed at year-end. A Resilience collaboration was announced in January 2023.
- Key risks include continuing losses, capital needs and potential shareholder dilution; clinical, regulatory and enrollment uncertainty; dependence on third-party manufacturers and research organizations; protection and continuation of Rutgers-licensed LNC intellectual property; competition, reimbursement and commercialization challenges. The company reported no pending legal proceedings and no material weakness in internal control; the auditor issued an unqualified opinion on the financial statements.
- After year-end, Silicon Valley Bank was closed. The company reported deposits there but said it did not expect a negative impact following the government announcement that depositors would have access to their funds.
Important facts for investors to verify
- Confirm current cash, securities, operating cash use and financing plans against subsequent filings; the stated runway was only through Q2 2024.
- Check final EnACT results and whether the planned MAT2203 Phase 3 trial received required regulatory, funding and operational support.
- Track the FDA’s feedback on the proposed broader invasive-fungal-infection program and whether non-dilutive financing or partners are secured.
- Assess the status of BioNTech and other collaborations, including any license, milestone or royalty agreements, rather than assuming research collaborations will produce future revenue.
- Review potential dilution from outstanding options (34.7 million at year-end), future equity financing and the available ATM capacity; also assess the Series A preferred-stock royalty rights described in the risk factors.